Company

FluoroPharma Medical, Inc.

Headquarters: Montclair, NJ, United States

Employees: 4

CEO: Dr. Thomas H. Tulip Ph.D.

OTC: FPMI

Detailed Description

FluoroPharma Medical, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of molecular imaging pharmaceuticals with initial applications in the area of cardiology in the United States. Its product candidates include BFPET, an imaging agent that has completed a Phase I clinical trial in stress-testing for patients with presumptive or proven coronary artery disease (CAD); and CardioPET, a molecular imaging agent, which is in Phase IIa clinical trial to assess myocardial blood flow and metabolism in patients with CAD. The company has license agreements with Massachusetts General Hospital and Sinotau USA; and clinical research agreements with Pharmaceutical Product Development, LLC, as well as Cardiovascular Imaging Technologies. FluoroPharma Medical, Inc. was founded in 2003 and is headquartered in Montclair, New Jersey.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

FluoroPharma Medical, Inc. has the following listings and related stock indices.


Stock: OTC: FPMI wb_incandescent

Details

Headquarters:

8 Hillside Avenue

Suite 108

Montclair, NJ 07042

United States

Phone: 973-744-1565